Koi o Shiranai Bokutachi wa

What the record establishes about Koi o Shiranai Bokutachi wa.

Antologia storica relativa alla scoperta della circolazione del sangue, fatta da Andrea Cesalpino / [Chelini Silvano]. is dated 1970 and held by Wellcome Collection. Rozwój nauki o chorobach układu krążenia w Polsce jako samodzielnej dyscypliny medycznej / Zbigniew Ruciński. is dated 1993 and held by Wellcome Collection. Syndrome der Kardiologie und ihre Schöpfer / Eberhard J. Wormer ; Geleitwort: E. Miles Vaughan Williams. is dated 1989 and held by Wellcome Collection. The current and future usefulness of noninvasive techniques in cardiology / Robert A. O'Rourke. is dated 1991 and held by Wellcome Collection. La querelle de la découverte de la circulation / A. Herpin ; préface de Noel Fiessinger. is dated 1943 and held by Wellcome Collection. Zyma Lexikon : Angiologie, Phlebologie / Myron G. Sulyma, Eberhard J. Wormer. is dated 1992 and held by Wellcome Collection.

O istorie a cardiologiei / Ioan Zăgrean. is dated 1993 and held by Wellcome Collection. O khirurgii serd︠t︡sa / A.N. Bakulev. is dated 1958 and held by Wellcome Collection. Wellcome Collection records 151 objects associated with this heading. Koi o Shiranai Bokutachi wa is associated with Japan.

Work associated with this heading is recorded in 1 named public collection.

Wellcome Collection: 151 recorded objects, read from the institution's own published catalogue.

5 scholarly publications naming this subject were located in the registry of record.

Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat., Mol Brain. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE., Blood. Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study., Blood Adv. Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis., Blood Adv. Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies., Blood Adv.

Bibliographic registers publish measured figures for this heading: 5 biomedical publications indexed (PubMed (National Library of Medicine)). A count of publications is evidence of attention, not of standing, and is given here only as a measure.

This article draws on 2 independent source lineages. Copies and mirrors of the same underlying record were collapsed into a single witness, so 2 means 2 genuinely separate publishers of record. 18 further registers were consulted and returned nothing for this heading.